In a Vaccine-Skeptical California County, a Potential Playbook To Contain Measles
Annie Sciacca / kffhealthnews - Conservative Shasta County stopped a measles outbreak from spreading, enlisting teachers, church leaders, and other trusted community members to get the public on board with health guidelines. Infectious disease specialists say the successful effort could…
AI Summary: Public health teams in a vaccine-hesitant California county deployed a targeted containment strategy—rapid case isolation, focused vaccination drives, community outreach and tailored messaging—to curb a measles flare-up. The approach balanced enforcement and engagement, showing that pragmatic, locally adapted tactics can control outbreaks even where vaccine acceptance is low.
Not just ovaries—new name for PCOS reflects the condition's multisystem nature
medicalxpress - An estimated 1 in 8 women live with polycystic ovarian syndrome, commonly referred to as PCOS. However, the name is a bit of a misnomer; it suggests that the condition affects only the ovaries. In actuality, the condition is a broader metabolic and hormon…
AI Summary: Medical experts announced a name change for polycystic ovary syndrome to better reflect its multisystem effects rather than framing it solely as an ovarian disorder. The update aims to reduce stigma, encourage holistic management of metabolic and psychological comorbidities, and align terminology with current scientific understanding of the condition.
Care navigation startup Garner Health banks $100M series E at $2.74B valuation
fiercehealthcare - The startup plans to use the capital to expand its provider quality platform, scale AI-powered product innovation and expand access.
AI Summary: Care navigation platform Garner Health closed a $100 million financing round to scale patient navigation and referrals to high‑performing clinicians, drawing strategic participation including Kaiser. The funding fuels expansion of tech‑enabled matchmaking between patients and clinicians while investors chase better outcomes and lower downstream costs.
American Cancer Society Updates Colorectal Cancer Screening Guideline: Major Changes Emphasize Blood-Based and At-Home Stool Testing
cancer - ACS researchers aim to reduce colorectal cancer deaths by offering options to improve screening participation
AI Summary: American Cancer Society revised colorectal screening guidelines, elevating at‑home stool testing and clarifying the role of blood‑based assays. Recommendations stress broader access to noninvasive stool tests while urging cautious, limited use of blood tests where appropriate, aiming to expand screening uptake without sacrificing diagnostic accuracy or overwhelming follow‑up resources.
- ACS guideline update: expanding stool tests, cautious blood-test role (7)
- Blood-based detection and ctDNA: trials shaping screening and treatment (4)
- All Other Stories
ACS guideline update: expanding stool tests, cautious blood-test role
Blood-based detection and ctDNA: trials shaping screening and treatment
All Other Stories
Walmart, Teladoc Team Up to Expand Access to Virtual Care
Marissa Plescia / medcitynews - Through a new partnership, Teladoc Health’s virtual services are now available on Walmart’s Better Care Services platform.The post Walmart, Teladoc Team Up to Expand Access to Virtual Care appeared first on MedCity News.
AI Summary: Walmart has integrated Teladoc’s virtual care services into its digital health platform, rolling out expanded telemedicine access through its channels. The partnership merges Teladoc’s clinical offerings with Walmart’s scale to lower barriers to care, steer routine visits online, and extend convenient virtual options to price‑sensitive consumers — because waiting rooms are so last century.
CMS Finalizes Rule to Simplify Payer-Provider Disputes Under No Surprises Act
Katie Adams / medcitynews - CMS finalized a new rule aimed at streamlining the No Surprises Act’s overwhelmed arbitration system. Provider groups largely welcomed the reforms — though some industry leaders said additional changes are still needed to address alleged misuse and improv…
AI Summary: The Centers for Medicare & Medicaid Services finalized a rule to simplify payer‑provider disputes under the No Surprises Act, updating the dispute resolution process and implementing a payer registry and portal changes. The aim is to reduce administrative friction, speed dispute handling, and make billing arbitration less of an endurance sport for providers and insurers.
- Final rule: new portal and payer registry details (3)
- Insurers push back; provider legal fights over payments (3)
- Patient fallout: medical debt and surprise billing stories (3)
Final rule: new portal and payer registry details
Insurers push back; provider legal fights over payments
Patient fallout: medical debt and surprise billing stories
Simple blood test could lead to personalized lung cancer treatment
medicalxpress - A single blood test could help doctors predict how lung cancer patients will respond to treatment before therapy begins, researchers have found. University of Queensland-led research focused on non-small cell lung cancer (NSCLC), the most common form of t…
AI Summary: Researchers describe a circulating cell-free methylated DNA liquid biopsy that can detect and track lung cancer by reading tumor-specific methylation patterns in blood. The minimally invasive test aims to guide personalized treatment choices, enable earlier detection of recurrence, and reduce dependence on tissue biopsies—basically doing the diagnostic heavy lifting while you sip your coffee.
- Blood tests for monitoring and personalizing lung cancer care (4)
- MCED trials and clinical benefit debate (4)
- Methylation liquid biopsy methods and applications (4)
- All Other Stories
Blood tests for monitoring and personalizing lung cancer care
MCED trials and clinical benefit debate
Methylation liquid biopsy methods and applications
All Other Stories
CVS sues to challenge new Tennessee PBM-pharmacy breakup law
Rebecca Pifer Parduhn / healthcaredive - The law, which would prohibit PBM conglomerates from owning or operating pharmacies, illegally boots out-of-state companies from Tennessee’s pharmacy market, CVS argued in suit filed Friday.
AI Summary: CVS Health has filed suit challenging Tennessee's new law that bars pharmacy benefit managers from owning pharmacies, arguing the measure unlawfully disrupts established business models and harms patient access. The company seeks to block enforcement while the legal fight plays out, setting up a clash between state regulators and a major healthcare middleman.
Smart ring maker Oura files confidentially for IPO as consumer demand propels revenue growth
fiercehealthcare - Oura, the smart ring maker, filed confidentially for an initial public offering after it reached an $11 billion valuation last year.
AI Summary: Ōura has quietly filed confidential paperwork to go public, leveraging surging consumer demand for its smart rings and an aggressive pivot into healthcare data and services. The company is pitching its wearable as a clinical-grade monitoring platform to insurers and providers, aiming to monetize sleep, activity and biometrics while navigating privacy and regulatory scrutiny.
How state laws can stymie research into your ancestors' psychiatric records
abcnews - Frustrated family members and others have been pushing for law changes in New York and other states that would allow the release of mental health records of long-dead ancestors
AI Summary: Legal researchers warn that a patchwork of state statutes and privacy rules is blocking access to historical psychiatric records needed for family‑history and population‑level studies. The restrictions complicate efforts to understand intergenerational mental‑health patterns and hamper reproducible research, leaving scientists to navigate inconsistent consent, archival access, and litigation risks.
Stem cells have potent potential for diabetes treatment
medicalxpress - Humans have around 30 trillion cells in our adult bodies. Amazingly, each of these cells came from a handful of about 100 stem cells in the earliest days of development. The ability of these embryonic stem cells to turn into any cell type makes them pluri…
AI Summary: Researchers report stem cell–based approaches can replenish insulin‑producing cells and restore glycemic control in diabetes models, offering a potential path beyond daily insulin injections. Early findings suggest significant therapeutic promise, but scientists stress that safety, durability, and immune‑rejection hurdles must be cleared before these techniques graduate from experimental hope to standard care.
An Ebola treatment tent is set ablaze again in eastern Congo with 18 suspected cases escaping
abcnews - A tent used for Ebola treatment in eastern Congo has been set on fire for the second time this week
AI Summary: In eastern Congo, an Ebola treatment tent was set ablaze, allowing at least 18 suspected patients to escape and disrupting outbreak containment efforts. The incident has drawn international scrutiny, with Congolese health officials publicly criticizing restrictive U.S. travel measures that complicate cross-border response and community trust.
Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop
Ayisha Sharma / endpoints - Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients. The small-molecule drug, known as BIIB122, missed the study’s ...
AI Summary: After disappointing mid‑stage results, developers have stopped advancement of a candidate Parkinson’s therapy for non‑genetic forms of the disease. The setback underscores the challenges of translating promising mechanisms into clinical benefit and will force sponsors to reassess pipelines and patient selection strategies.
Abridge names chief technology officer
Giles Bruce / beckershospitalreview - San Oo has been named chief technology officer of healthcare AI startup Abridge. Mr. Oo was most recently senior vice president of engineering at AI workspace developer Notion. He previously cofounded two tech companies that were acquired by LinkedIn and …
AI Summary: Abridge has appointed a new chief technology officer to lead its product and engineering strategy, signaling a push to scale its clinical AI tools and platform capabilities. The hire aims to strengthen technical leadership, accelerate development timelines, and reassure customers that the company intends to keep up with the fast-paced demands of healthcare AI — which, ironically, keeps hiring to stop churn.
- AI startups scale via health system partnerships (4)
- Practical challenges: accessibility, training, oversight of clinical AI (6)
- All Other Stories
AI startups scale via health system partnerships
Practical challenges: accessibility, training, oversight of clinical AI
All Other Stories
CommonSpirit $3.4B in the red amid billing contract exit, operational woes
Rebecca Pifer Parduhn / healthcaredive - The Catholic nonprofit giant’s expenses well outstripped revenue in the most recent financial quarter. Though the outcome was mostly due to one-time items, CommonSpirit also continues to struggle with boosting core operations.
AI Summary: CommonSpirit reported a multi‑billion‑dollar shortfall tied to operational challenges and the exit from a major billing contract, recording a substantial loss and a weakened operating margin in the quarter. The results have spurred leadership to reassess financial strategy and cost controls as the system navigates recovery and operational stabilization.
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
Lei Lei Wu / endpoints - The FDA has approved the TROP2-directed antibody-drug conjugate Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor Gilead. The approval marks Datroway’s third, after ...
AI Summary: Daiichi Sankyo and AstraZeneca’s breast cancer therapy Datroway has cleared key regulatory hurdles, winning FDA approval and earning backing from European regulators. The approvals validate pivotal trial results and pave the way for clinical adoption in the indicated patient population, prompting clinicians to prepare for integration into treatment pathways and health systems to weigh formulary and access decisions.
- Clinicians weigh Datroway’s role in TNBC care (3)
- FDA win and market stakes for Datroway (3)
- All Other Stories
Clinicians weigh Datroway’s role in TNBC care
FDA win and market stakes for Datroway
All Other Stories
Nearly 10% of surgeons are leaving the profession within 8 years
medicalxpress - Surgeons are an integral part of the health care system, supplying critical and urgent care in nearly every field of medicine. But surgeons are already in short supply, with the gap between the number needed and the number working expected to get worse.
AI Summary: A recent report reveals that roughly one in ten surgeons leave clinical practice within eight years of starting, spotlighting a troubling attrition rate that threatens surgical capacity. The findings point to burnout, workload and systemic pressures as likely drivers and underscore the need for retention strategies, training support and policy changes to stabilize the surgical workforce.
Adding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer
Kathleen Medora / aacr - CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis PHILADELPHIA – A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic canc…
AI Summary: Researchers propose lowering the CA19‑9 threshold to identify additional patients at high risk for pancreatic cancer. The analysis indicates the new cutoff improves detection of potentially dangerous cases without an unmanageable rise in false positives, offering a straightforward diagnostic tweak that could prompt earlier workups and treatment decisions.
Providence shuts down most insurance businesses for 2027
Rebecca Pifer Parduhn / healthcaredive - The nonprofit giant has offered health insurance for decades. But recent challenges, including higher costs and regulatory changes, have placed Providence in an untenable position, according to the integrated system’s CEO.
AI Summary: Providence announced plans to shut down or substantially scale back its insurance businesses by 2027, citing unsustainable operations and strategic misalignment. The health system will refocus on core care delivery, a move that will ripple through regional insurance markets, affect covered members, and require careful transition planning to maintain access.
BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test
Reynald Castaneda / endpoints - BioMarin’s enzyme replacement therapy for a rare genetic disorder called ENPP1 deficiency delivered mixed results in a late-stage study. Patients with the condition don't produce enough of the ENPP1 enzyme, which generates plasma inorganic pyrophosphate .…
AI Summary: BioMarin reported a Phase 3 trial that failed to show clinical benefit for a rare‑disease therapy, undermining prior optimism and clouding the drug’s development pathway. The mixed late‑stage results force a strategic reassessment, cooling investor expectations and leaving researchers and patients waiting for next steps or alternative approaches.